Caisse DE Depot ET Placement DU Quebec Sells 6,485,010 Shares of Pfizer Inc. (NYSE:PFE)

Caisse DE Depot ET Placement DU Quebec decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 69.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,816,122 shares of the biopharmaceutical company's stock after selling 6,485,010 shares during the quarter. Caisse DE Depot ET Placement DU Quebec's holdings in Pfizer were worth $74,712,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Virtu Financial LLC bought a new position in Pfizer in the 3rd quarter valued at about $1,499,000. World Investment Advisors LLC boosted its holdings in shares of Pfizer by 61.1% in the third quarter. World Investment Advisors LLC now owns 127,265 shares of the biopharmaceutical company's stock valued at $3,683,000 after acquiring an additional 48,281 shares in the last quarter. Tidal Investments LLC increased its stake in shares of Pfizer by 13.1% during the third quarter. Tidal Investments LLC now owns 190,628 shares of the biopharmaceutical company's stock valued at $5,517,000 after acquiring an additional 22,068 shares during the period. Trust Co of the South raised its holdings in Pfizer by 6.1% during the fourth quarter. Trust Co of the South now owns 28,945 shares of the biopharmaceutical company's stock worth $768,000 after purchasing an additional 1,667 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in Pfizer by 53.3% in the fourth quarter. Versant Capital Management Inc now owns 6,799 shares of the biopharmaceutical company's stock worth $180,000 after purchasing an additional 2,365 shares during the period. Institutional investors own 68.36% of the company's stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.06% of the company's stock.

Pfizer Stock Up 1.1 %

Pfizer stock traded up $0.26 during mid-day trading on Friday, hitting $24.19. The company's stock had a trading volume of 41,672,273 shares, compared to its average volume of 40,490,154. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54. The firm's 50 day moving average is $24.34 and its 200 day moving average is $25.75. The company has a market cap of $137.19 billion, a PE ratio of 17.16, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm posted $0.82 earnings per share. The firm's revenue was down 7.8% on a year-over-year basis. On average, analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 annualized dividend and a dividend yield of 7.11%. Pfizer's payout ratio is 124.64%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PFE. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price objective on the stock. The Goldman Sachs Group restated a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group increased their target price on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a research note on Wednesday. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.